GH Research (GHRS) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GH Research (GHRS) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 60.9% versus a gain of 16.7%. Rapport Therapeutics is the larger company by market cap ($1.43 billion vs $1.38 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | RAPP |
|---|---|---|
| Share price | $20.05 | $29.76 |
| Market cap | $1.38B | $1.43B |
| 1-day change | -4.82% | -3.56% |
| YTD return | +65.83% | +1.71% |
| 1-year return | +60.89% | +16.72% |
| 5-year return | +23.88% | — |
| EPS (TTM) | $-0.99 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.44 | $52.93 |
| 52-week low | $12.04 | $23.75 |
| Distance from 52-week high | -36.24% | -43.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +113.97% | +111.83% |
| Average volume | 296.90K | 359.60K |
| Shares outstanding | 68.64M | 47.98M |
| Employees | 73 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed RAPP by 44.2 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
GHRS vs RAPP FAQ
Which is bigger, GH Research or Rapport Therapeutics?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.43B compared with $1.38B for GH Research (GHRS).
Which stock has performed better over the past year, GHRS or RAPP?
GHRS returned +60.89% over the past 12 months, compared with +16.72% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.